Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;45(4):312-328.
doi: 10.1016/j.nefroe.2025.03.002. Epub 2025 Apr 2.

Spanish Registry of Renal Patients: 2022 Report and evolutive analysis

Borja Quiroga  1 , Beatriz Mahíllo  2 , Auxiliadora Mazuecos  3 , Alberto Ortiz  4 , Jordi Comas Farnés  5 , Domingo Hernández Marrero  6 , Sara Trujillo Alemán  7 , M Carmen Santiuste de Pablos  8 , Olga Lucía Rodríguez Arévalo  9 , María Marques Vidas  10 , M Fernanda Slon-Roblero  11 , Marta Artamendi Larrañaga  12 , Iñigo Moina Eguren  13 , María de la Oliva Valentín Muñoz  14 , Marta Rodríguez Camblor  15 , Inmaculada Moreno Alia  16 , Mª Encarnación Bouzas Caamaño  17 , Mª Antonia Blanco Galán  18 , Javier Deira Lorenzo  19 , Héctor García López  20 , Federico Eduardo Arribas Monzon  21 , Gonzalo Gómez Marqués  22 , Alberto Rodríguez-Benot  23 , Beatriz Domínguez-Gil  24 , Emilio Sánchez Álvarez  25 ; en nombre de todos los representantes del REER
Affiliations
Free article

Spanish Registry of Renal Patients: 2022 Report and evolutive analysis

Borja Quiroga et al. Nefrologia (Engl Ed). 2025 Apr.
Free article

Abstract

Introduction: Chronic kidney disease (CKD) will be the second leading cause of death in Spain by 2100. The Spanish Renal Disease Registry (REER) records the incidence, prevalence and mortality of all patients requiring renal replacement therapy (RRT) in Spain.

Methods: Data are provided by Spanish autonomous regions and cities and the Organización Nacional de Trasplantes. Incidence and prevalence rates of RRT have been calculated (considering the Spanish population according to annual data from the Instituto Nacional de Estadística), as well as mortality of patients on RRT in our country during the period 2013-2022.

Results: The incidence rate of RRT increased by 21% from 2013 to 2019, and stabilized thereafter, with a value of 152.2 cases per million population (pmp) in 2022, of which 77.8% were on haemodialysis (HD), 16.7% on peritoneal dialysis (PD) and 5.5% received a preemptive kidney transplant. Diabetes was the leading cause of CKD requiring RRT (21.8%), followed by other causes (21.6%). The incidence rate of RRT was 2-fold higher in men than in women, with large regional differences (1.93-fold for men and 2.55-fold for women in regions with the highest and lowest incidence rates). The prevalence rate of RRT was 1,391.1 pmp in 2022, showing a progressive increase over the last decade, mainly at the expense of an increase in the transplant population (765.0 pmp, 55.0%). In 2022, 3,404 kidney transplants were performed in Spain (71.7 pmp), which situates it as a world leader. The most frequent donor type was the donor after the neurological determination of death (51.5%), followed by the donor after the circulatory determination of death (37%). The overall annual mortality of RRT patients was 8.4% (13.8% for HD, 10.1% for PD and 3.9% for transplantation).

Conclusions: Although it has stabilized somewhat in recent years, the incidence and prevalence of RRT continues to rise in Spain. Additional measures must be adopted to harmonize and optimize kidney health care.

Keywords: Chronic kidney disease; Enfermedad renal crónica; Epidemiology; Epidemiología; Incidence; Incidencia; Kidney replacement therapy; Mortalidad; Mortality; Prevalence; Prevalencia; Registro; Registry; Terapia renal sustitutiva.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest BQ is the current registry coordinator of the Spanish Society of Nephrology (S.E.N.) and has received funding/honoraria from Sandoz, Novo Nordisk, Otsuka, AstraZeneca, Boehringer and CSL-Vifor. AO has received funding from Sanofi and consulting fees or for lectures or travel support from Adviccene, Alexion, Astellas, AstraZeneca, Amicus, Amgen, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma, and is Director of the UAM-AstraZeneca Chair of Chronic Kidney Disease and Electrolytes. He holds shares in Telara Farma. AM is a member of the Board of Directors of the Spanish Society of Nephrology (S.E.N.) and has received funding/honoraria from GSK, Sandoz, Astellas, Sanofi, Otsuka and AstraZeneca. ES is the current president of the Spanish Society of Nephrology (S.E.N.) and has received funding/honoraria from Novo Nordisk, AstraZeneca, Boehringer and CSL-Vifor. MM is the current president of the Madrid Society of Nephrology and member of the Committee of the Madrid Registry of Renal Patients (REMER) and has received fees for collaboration in teaching and training and/or scientific advice from Alexion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, CSL-Vifor, Esteve, GSK, Menarini and NovoNordisk. ARB is president of the Andalusian Society of Organ and Tissue Transplantation. He has received funding/honoraria from Astellas Farma, Chiesi, GSK and Novo Nordisk. MVM has received funding/honoraria from Fresenius, Sandoz and Sanofi. BMD, DH, STA, MCSP, OLRA, MFSR, IME, MRC, IMA, EBC, MABG, JDL, HGL, FEAM and GGM have no conflict of interest.

References

LinkOut - more resources